Skip to main content
Log in

Drug-Induced Orthostatic Hypotension

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Drug-induced orthostatic hypotension is an important clinical problem. When symptomatic, it is poorly tolerated by the patient, and can be a cause for discontinuing treatment. It may have more serious consequences if it leads to syncope, falls and injury, or to sustained loss of perfusion of vital organs resulting in heart attack or stroke.

Orthostatic hypotension is easily detected by procedures available to all physicians, who should maintain a high index of suspicion when prescribing drugs commonly known to cause this condition, especially in the elderly. Since the medical conditions calling for the use of these drugs are extremely prevalent, the screening and monitoring of orthostatic hypotension should be instituted as a routine precaution in appropriate patients.

Hypertension affects two-thirds of elderly patients. Orthostatic hypotension is an infrequent adverse effect of most of the drugs in current use in the treatment of hypertension; it is, however, more common with α1-blockers (first dose), adrenergic blockers and centrally acting drugs. Sudden loss of blood volume, or excess diuresis, may precipitate orthostatic hypotension in any hypertensive patient.

Drugs used for the treatment of psychiatric illnesses are all associated with a significant incidence of orthostatic hypotension: phenothiazines, tricyclic antidepressants and monoamine oxidase inhibitors. Cardiovascular drugs associated with hypotension include dopamine agonists, antianginals and antiarrhythmics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Baldessarine RJ. Drugs and the treatment of psychiatric disorders. In Gilman et al. (Eds) The pharmacologic basis of therapeutics, MacMillan, New York, 1985

    Google Scholar 

  • Brunner HR, Waeber B, Nussberger J. Principles and practice of angiotensin-converting enzyme inhibitors. In Messerli (Ed). Cardiovascular drug therapy, pp. 732–760, W.B. Saunders Co., Philadelphia, 1990

    Google Scholar 

  • Campbell AJ. Drug treatment as a cause of falls in old age. A review of the offending agents. Drugs & Aging 1: 289–302, 1991

    Article  CAS  Google Scholar 

  • CAST (Cardiac Arrhythmia Suppression Trial) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New England Medical Journal 312: 406–412, 1989

    Google Scholar 

  • Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States: the National Health and Nutrition Examination Survey I, Epidemiologic Follow-up Study (1982–1984). Archives of Internal Medicine 149: 780–788, 1989

    Article  PubMed  CAS  Google Scholar 

  • Editorial. Report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure. Archives of Internal Medicine 148: 1023–1038, 1988

    Article  Google Scholar 

  • Frishman WH. Beta-adrenergic blockers. Medical Clinics of North America 72: 37–54, 1988

    PubMed  CAS  Google Scholar 

  • Mader SL. Aging and postural hypotension. Journal of the American Geriatric Society 37: 129–137, 1989b

    CAS  Google Scholar 

  • Mader SL. Orthostatic hypotension. Medical Clinics of North America 73: 1337–1349, 1989a

    CAS  Google Scholar 

  • McMahon GF. Alpha1blocking agents. In Management of essential hypertension,chapter IX, pp. 501–531, Futura Publishing Co., Mt Kisco, 1990c

    Google Scholar 

  • McMahon GF. Calcium channel blockers. In Management of essential hypertension,chapter III, pp. 117–175, Futura Publishing Co., Mt Kisco, 1990

    Google Scholar 

  • McMahon GF. Diuretics. In Management of essential hypertension, chapter VI, pp. 297–378, Futura Publishing Co., Mt Kisco, 1990a

    Google Scholar 

  • McMahon GF. Vasodilators. In Management of essential hypertension, Chapter X, pp. 533–570, Futura Publishing Co., Mt Kisco, 1990d

    Google Scholar 

  • Prichard BNC. Antidrenergic therapy. In Messerli (Ed.) Cardiovascular drug therapy, pp. 624–640, W.B. Saunders Co., Philadelphia, 1990.

    Google Scholar 

  • Shakenovich A, Scheidt S. Long-acting nitrates. In Messerli (Ed.) Cardiovascular Drug Therapy, W.B. Saunders, Philadelphia, 1990

    Google Scholar 

  • Young JB, Leon CA. Fenoldopam. In Messerli (Ed.) Cardiovascular drug therapy, W.B. Saunders, Philadelphia, 1990

    Google Scholar 

  • Ziegler MG. Therapy for postural hypotension. In Messerli (Ed.) Cardiovascular drug therapy, pp. 1608–1617, W.B. Saunders Co., Philadelphia, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schoenberger, J.A. Drug-Induced Orthostatic Hypotension. Drug-Safety 6, 402–407 (1991). https://doi.org/10.2165/00002018-199106060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199106060-00002

Keywords

Navigation